



Insights Into Thyroid Cancer

April 3, 2023

Chair: Lori Wirth, MD

AGENDA

Time (ET)	Topic
6.00 PM – 6.15 PM (15 min)	Introduction <ul style="list-style-type: none"> • Program overview and objectives • ARS questions
6.15 PM – 6.35PM (20 min)	Management of RAI-Refractory or Ineligible Disease (mDTC) <ul style="list-style-type: none"> • Overview of: <ul style="list-style-type: none"> – Thyroid cancer epidemiology <ul style="list-style-type: none"> ▪ DTC vs medullary and anaplastic – Determining RAI applicability – Genomic testing for actionable mutations <ul style="list-style-type: none"> ▪ <i>ALK, NTRK, RET</i> – Initial VEGFR-targeting systemic therapy <ul style="list-style-type: none"> ▪ Lenvatinib ▪ Sorafenib
6.35 PM – 7.05 PM (30 min)	Moderated Discussion
7.05 PM – 7.15 PM (10 min)	Break
7.15 PM – 7.45 PM (30 min)	Second-Line Systemic Therapy <ul style="list-style-type: none"> • ARS Questions • Overview of: <ul style="list-style-type: none"> – Assessment after initial therapy – Impact of prior therapy on subsequent treatment choice – Options post VEGFR-targeting therapy <ul style="list-style-type: none"> ▪ Cabozantinib (COSMIC-311) – Sequencing of therapies – AE management
7.45 PM – 8.45 PM (60 min)	Moderated Discussion
8.45 PM – 9.00 PM (15 min)	Key Takeaways and Meeting Evaluation